CN113332365A - 一种复方紫草膏及其制备方法 - Google Patents
一种复方紫草膏及其制备方法 Download PDFInfo
- Publication number
- CN113332365A CN113332365A CN202110775213.1A CN202110775213A CN113332365A CN 113332365 A CN113332365 A CN 113332365A CN 202110775213 A CN202110775213 A CN 202110775213A CN 113332365 A CN113332365 A CN 113332365A
- Authority
- CN
- China
- Prior art keywords
- parts
- lithospermum
- compound
- ointment
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001071917 Lithospermum Species 0.000 title claims abstract description 80
- 239000002674 ointment Substances 0.000 title claims abstract description 80
- 150000001875 compounds Chemical class 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 66
- 229940079593 drug Drugs 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 22
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 22
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 229940116229 borneol Drugs 0.000 claims abstract description 20
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 20
- 235000011477 liquorice Nutrition 0.000 claims abstract description 20
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 19
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 18
- 239000010495 camellia oil Substances 0.000 claims abstract description 18
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 17
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 17
- 235000013871 bee wax Nutrition 0.000 claims abstract description 17
- 240000004980 Rheum officinale Species 0.000 claims abstract description 16
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 16
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 92
- 239000000463 material Substances 0.000 claims description 86
- 239000000284 extract Substances 0.000 claims description 64
- 238000001179 sorption measurement Methods 0.000 claims description 53
- 239000011347 resin Substances 0.000 claims description 48
- 229920005989 resin Polymers 0.000 claims description 48
- 238000000605 extraction Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 27
- 241000196324 Embryophyta Species 0.000 claims description 22
- 238000007873 sieving Methods 0.000 claims description 20
- 244000173853 Sanguisorba officinalis Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- 238000007670 refining Methods 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000012166 beeswax Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 241000130781 Arnebia Species 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 54
- 208000002193 Pain Diseases 0.000 abstract description 27
- 230000036407 pain Effects 0.000 abstract description 27
- 230000008961 swelling Effects 0.000 abstract description 19
- 230000008901 benefit Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract description 4
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 240000004064 Poterium sanguisorba Species 0.000 abstract 2
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 40
- 206010052428 Wound Diseases 0.000 description 27
- 208000027418 Wounds and injury Diseases 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 26
- 108090000604 Hydrolases Proteins 0.000 description 19
- 102000004157 Hydrolases Human genes 0.000 description 19
- 206010042674 Swelling Diseases 0.000 description 18
- 206010053615 Thermal burn Diseases 0.000 description 16
- 206010015150 Erythema Diseases 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 231100000321 erythema Toxicity 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 206010037844 rash Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000005884 exanthem Diseases 0.000 description 7
- 208000001297 phlebitis Diseases 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 4
- 206010011985 Decubitus ulcer Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000004210 Pressure Ulcer Diseases 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 238000002525 ultrasonication Methods 0.000 description 4
- 239000004229 Alkannin Substances 0.000 description 3
- 241000130784 Arnebia euchroma Species 0.000 description 3
- 241000218202 Coptis Species 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 206010011469 Crying Diseases 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019232 alkannin Nutrition 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000009416 jing wan hong Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- LRFDUPNLCDXZOE-UHFFFAOYSA-N camellianin b Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC=2C=3C(=O)C=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)OC1CO LRFDUPNLCDXZOE-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000581682 Sanguisorba Species 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 201000004169 miliaria rubra Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种复方紫草膏及其制备方法。以重量份计,所述复方紫草膏包括如下组分:紫草30~50份、黄连50~75份、大黄40~55份、虎杖40~55份、地榆30~45份、白芷25~35份、生甘草20~30份、山茶油450~500份、蜂蜡80~100份和冰片10~15份;本发明中,以黄连,紫草为君药;大黄,虎杖为臣药,地榆为佐药;白芷,甘草,冰片为使药;各组分配伍相得益彰,疗效确切,具有清热燥湿,消肿定痛,抑菌消炎,润肤生肌的效果;该发明成分明确,安全可靠,未见明显毒副作用,同时制备工艺简单,各项指标可控,易于推广及改进,具有良好的社会及经济效益。
Description
技术领域
本发明属于中医药技术领域,具体涉及一种复方紫草膏及其制备方法。
背景技术
皮肤创伤如烧烫伤、擦伤、皮肤溃疡、粘膜损伤是外科临床的常见病。浅表的外伤、烧烫伤可自行居家治疗,这对于节约门诊医疗资源,减轻社会经济负担有良好的意义。浅表外伤的治疗通常采用清创、消毒、敷药、包扎以及手术治疗,所采用西药主要为抗感染、收敛、促进表皮生长药物。当创面较大时,由于引流不畅,药物渗透性较差,耐药菌定植等原因,创面可能会浸渍、感染,换药时纱布粘至创面,导致疼痛,出血等症状的产生,进而导致疗程长、愈合慢,形成瘢痕甚至需要植皮,治疗费用高。并且,国内外使用的抗菌药物由于滥用等各种原因,导致了细菌对药物的耐药性,临床上常可见到耐甲氧西林金葡菌,表皮葡萄球菌等多重耐药细菌感染所导致的创面化脓,使得疗程迁延,治疗费用进一步增高。
天然草药中已分离出许多有抑菌、杀菌活性的物质,对于多重耐药细菌仍有明显抑制效果,所以开发和研究新的天然抗菌药物就越来越受到人们的重视。传统医学认为化脓性感染是外感邪毒阻为皮肉之间,以致营于不和、经络阻隔、气血凝滞。临床上表现为:皮肤破损处红肿热痛,疮面见有脓性分泌物,局部焮赤红肿并向四周蔓延,伴有发热、口渴、心烦等症状;其病机在于:毒邪蕴结阻于皮肉之间,临床上通过辩证采取清热解毒、收湿敛疮作为治疗立论,配合局部扶正驱邪,取得了较好的治疗效果并降低了治疗费用。
紫草膏从外观上看来是一种紫红色软膏,具有特殊的油腻气,外用,其最主要的成分为紫草,而紫草根含紫草素,可入药,治麻疹不透、斑疹、便秘、腮腺炎等症,外用治烧烫伤。传统制备紫草膏的工艺中,多采用油炸法,将紫草等中药材在高温(250℃左右)条件下炸至紫红色以提取紫草中的有效成分紫草素,经过去渣、过滤等步骤得到紫草油,然后加入适量熔化后的蜂蜡,混合均匀,冷却后得到。此法以植物油为溶媒,在高温下提取紫草中的有效成分,紫草素在高温下极易被分解破坏,影响药物疗效,并且现有的紫草膏功效单一,适用病症较少。因此,有必要开发一种配方经济、功效安全、适用病症较广的复方紫草膏。
发明内容
本发明的目的在于克服现有技术的不足,提供一种复方紫草膏及其制备方法。本发明所述的复方紫草膏,各组分配伍相得益彰,疗效确切;该发明成分明确,安全可靠,未见明显毒副作用,同时制备工艺简单,各项指标可控,易于推广及改进,具有良好的社会及经济效益。
本发明的一个目的在于提供一种复方紫草膏。
一种复方紫草膏,以重量份计,包括如下组分:紫草30~50份、黄连50~75份、大黄40~55份、虎杖40~55份、地榆30~45份、白芷25~35份、生甘草20~30份、山茶油450~500份、蜂蜡80~100份和冰片10~15份。
进一步地,以重量份计,所述复方紫草膏包括如下组分:紫草40份、黄连60份、大黄50份、虎杖50份、地榆35份、白芷30份、生甘草25份、山茶油480份、蜂蜡90份和冰片12份。
本发明的另一个目的在于提供一种复方紫草膏的制备方法。
一种复方紫草膏的制备方法,包括如下步骤:
S1、以重量份计,将50~75份黄连、40~55份大黄、40~55份虎杖、30~45份地榆和20~30份生甘草分别粉碎、过筛网,之后混合,得到物料A;将30~50份紫草和25~35份白芷分别粉碎、过筛网,之后与450~500份山茶油混合,得到物料B;将10~15份冰片粉碎、过筛网,得到物料C;将80~100份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加乙醇,植物复合水解酶,之后置于超声破碎仪中恒温酶解后,过滤、减压回收,得到混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,经喷雾干燥后,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D混合均匀,过筛后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
进一步地,所述制备方法还包括原料预处理步骤,具体是将黄连、大黄、虎杖、地榆、生甘草、白芷和紫草经清洗、除杂后,控水25~40min,之后置于60~70℃的烘箱内烘干。
进一步地,步骤S1中,所述物料A中的原料过50~80目筛网;所述物料B中的紫草和白芷过30~50目筛网;所述物料C中的原料过100~120目筛网。
进一步地,步骤S2中,所述乙醇的质量浓度为60~70%,所述乙醇的添加量为物料A体积的6~8倍,所述植物复合水解酶的终浓度为2.5~3U/ml,之后调节溶液的pH至5.0~6.0之间。
进一步地,步骤S2中,所述超声破碎仪的参数如下:温度45~60℃、频率40±5KHz、功率300±10W,超声破碎2~3h,之后过滤得到滤液,再向药渣中加入4~6倍体积的质量浓度为60~70%的乙醇回流提取2~4h,收集回流提取液并合并两次的药液,在-0.04Mpa,70℃的条件下减压回收乙醇,浓缩至相对密度为1.10~1.15的混合浸膏。
进一步地,步骤S2中,所述大孔树脂吸附法对所述混合浸膏进行精制的步骤如下:将浸膏分散溶解于水中,使浸膏水溶液浓度为0.5~1g/ml;以质量浓度为5%的乙醇洗脱1~3倍树脂体积进行大孔吸附树脂串联吸附柱(D-101和AB-8)预处理除杂,然后将所述浸膏水溶液通过所述大孔吸附树脂串联吸附柱,浸膏水溶液上样量与树脂量之比为1:10,吸附流速为3~9BV/h,吸附完成后,用质量浓度为70%的乙醇洗脱4~6倍树脂体积,洗脱流速为3~9BV/h,收集乙醇洗脱液,在-0.04Mpa,70℃的条件下下减压回收乙醇,经喷雾干燥,制得中药粉剂。
进一步地,步骤S3中,所述微波提取器的提取参数如下:700~800W的功率,提取15~30min。
进一步地,步骤S4中,所述混合均匀的温度为70~80℃,筛网的规格为80~100目。
本发明中,以黄连与紫草作为本方剂的君药。黄连味苦,性寒;功效清热燥湿,泻火解毒,除中焦湿热,“诸疮必用”;黄连具有很强的抗菌、抗内毒素,抗病毒,抗炎、抗腹泻作用;还兼有有抗癌、抗溃疡、免疫调节作用。紫草性寒,味甘、咸;清热凉血,活血解毒,透疹消斑;并具有抗炎,改善循环,活血消肿、镇痛作用,能控制体液外渗,减少液体流失,具有促进上皮生长,加快创面愈合的效果。二药协同作用,对血热毒盛,斑疹麻疹,疮疡,湿疹,水火烫伤等多种体表病变,均可取得一定效果。
以大黄,虎杖作为本方剂的臣药。大黄味苦,性寒;清热泻火,凉血解毒,逐瘀通经;临床用于火毒疮疡,外治烧烫伤,溃疡、口腔炎及毛囊炎;现代研究具有抗真菌、抗病毒,抗炎,止血作用,双向调节免疫作用,此外还能抗油脂氧化。虎杖味微苦,性微寒,归肝、胆、肺经;外用清热解毒,散瘀止痛,凉血止血、解毒敛疮,内服能利湿退黄,止咳化痰;虎杖具有收敛效果,可使渗出液减少,兼有止血和抗感染作用,有利于创面愈合。二药均具有活血散瘀、清热解毒、利胆退黄、泻下通便的功效,常用于治疗瘀血诸证、痈肿疮毒、水火烫伤、湿热黄疸、淋证、热结便秘等;臣药加强了君药的清热解毒作用,大黄苦降,更清下焦湿热,标本兼治。
以地榆作为本方剂的佐药。地榆性微寒,味苦、酸、涩;凉血止血、解毒敛疮,入于下焦血分除热;外用用于治疗疮疡、水火烫伤,便血痔血;地榆可使创面收敛,渗出液减少,对创面起到良好的隔离与保护作用,配合君臣药之效用,利于各类创面的愈合。
以白芷,甘草,冰片作为本方剂的使药。白芷性温味辛,归胃、大肠、肺经;白芷性温味辛,归胃、大肠、肺经;白芷主要用于祛风、散寒、燥湿和止痛,外用消肿拔脓,促进肌肤生长。甘草味甘性平,调和诸药,能泻火缓急,散表邪,消痈肿。冰片性微寒,味辛、苦。具有开窍醒神,清热散毒、防腐生肌功效,能帮助药物的透皮吸收;外用具有止痒消炎、消肿止痛作用,治疗疮疡肿痛,水火烫伤,溃后不敛效果较好。甘草调和,白芷辛香行气,冰片辛凉走窜,促进药物分布吸收,共奏药效。
以山茶油和蜂蜡作为膏体基质。蜂蜡味甘性平,《神农本草经》将其列为医药“上品”,能解毒,敛疮,生肌,止痛。外用于溃疡不敛,臁疮糜烂,外伤破溃,烧烫伤的治疗。山茶油《本草纲目》记载其“性寒凉,味甘平,润肠通便,清热化湿,润肺祛痰,利头目”;山茶油含有大量不饱和脂肪酸,还含有山茶甙、茶多酚、皂甙、鞣质及角鲨烯,维生素E和钙、铁、锌等微量元素;所含角鲨烯与皮肤相容性好,无刺激性和过敏性,有助于保持皮肤的柔软,改善皮肤色泽,促进药物经皮吸收;所含不饱和脂肪酸具有抗氧化及调节免疫功能,并对细菌、霉菌和酵母均有抑制作用;山茶油具有清热抗炎、抗菌,抗紫外线,防止晒斑及减轻皱纹的特殊功效。
与现有技术相比,本发明具有如下优点:
1)本发明所述的复方紫草膏,各组分配伍相得益彰,疗效确切;该发明成分明确,安全可靠,未见明显毒副作用,同时制备工艺简单,各项指标可控,易于推广及改进,具有良好的社会及经济效益。
2)本发明中,以黄连,紫草为君药;大黄,虎杖为臣药,地榆为佐药;白芷,甘草,冰片为使药;各组分配伍相得益彰,疗效确切,具有清热燥湿,消肿定痛,抑菌消炎,润肤生肌的效果。药物制作成油膏剂,具有柔软、滑润又无板着粘腻不爽之感,防止创面水分丢失,维持创面一定的湿度,使创面在近似生理环境下修复;创面保持湿润时间长,更换敷料时患者疼痛不明显、易于接受,并且不损伤新生表皮组织,为创面的再生修复提供了有利条件。
附图说明
为了更清楚地说明本发明实施例中的技术方案,下面将对实施例描述中所需要使用的附图作简单的介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明复方紫草膏制备流程图。
具体实施方式
下面将结合本发明实施例中的附图对本发明实施例中的技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例,基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明所使用的试剂和设备,如无特殊说明,均可市售获得。
中药制剂最为关键的步骤是对活性成分的提取和分离,它决定着中药制剂的质量、疗效和产量。传统中药提取方法,如煎煮法、回流提取法、浸渍法、渗漉法以及连续提取法等。而这些方法都存在较大的缺陷,比如杂质清除率低、有机溶剂消耗量大、环境污染严重、活性成分提取率低且能耗高等,这使得中药制药的发展受到的极大的阻碍。并且,未经精制提纯的中药成品往往存在“粗,大,黑”的劣势,品质控制欠佳,难以适应标准化生产的需求。
基于此,本发明公开了一种复方紫草膏的制备方法,包括如下步骤:
S1、以重量份计,将50~75份黄连、40~55份大黄、40~55份虎杖、30~45份地榆和20~30份生甘草分别粉碎、过筛,之后混合,得到物料A;将30~50份紫草和25~35份白芷分别粉碎、过筛,之后与450~500份山茶油混合,得到物料B;将10~15份冰片粉碎、过筛,得到物料C;将80~100份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加乙醇,植物复合水解酶,之后置于超声破碎仪中恒温酶解后,过滤、减压回收,得到混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,经喷雾干燥后,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D混合均匀,过筛后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
本发明所采用的提取有效成分的方式符合科学研究的提取工艺,并兼顾了工业化生产的高效、低成本、污染较小的工艺。
本发明所述的复方紫草膏,以乙醇作为浸出中药有效成分的溶剂,在溶出水溶性及脂溶性成分同时,有效减少药材中如淀粉、蛋白质、粘液等杂质的浸出,对于根茎类药材尤为适宜。同时,乙醇价廉、低毒、容易回收,质量浓度为20%以上的乙醇还可以起到防腐和防止溶液变质的功效。
用酶解法结合超声提取技术,能有效提升目标产物浓度。超声具有空化效应、热效应和机械作用;利用超声波的空化作用加速植物有效成分的浸出提取,超声波的次级效应,如机械振动、乳化、扩散、击碎、化学效应等也能加速欲提取成分的扩散释放,并充分与溶剂混合,利于提取;加入一定量的植物复合水解酶(纤维素酶、果胶酶)可以破坏细胞壁结构,使提取传质阻力减小,利于有效成分的释放;与常规提取法相比,酶解法结合超声提取技术具有提取时间短、产率高、无需高温加热等优点。
大孔吸附树脂技术是近20年来发展的重要提纯手段,纯化后固体物中中药有效成分含量高,工艺简便、成本低、易于工业化大生产,还能脱去药材中的铅、镉、铜、汞。在节约能源和提高药品质量方面具有极大的优势,有很好的推广应用前景。本发明中使用的D-101型大孔吸附树脂是苯乙烯型非极性共聚体,适用范围广,对于不带极性的有机化合物吸附能力强,特别对皂甙类分离,纯化效果尤佳,对黄酮类也很适宜;AB-8型大孔吸附树脂是苯乙烯型弱极性共聚体,最适宜用于具有弱极性物质的提取、分离、纯化,如各种生物碱,白藜芦醇等。将D-101与AB-8树脂提取柱串联提取,能够基本覆盖该发明中有效成分的提取,并能节约资源,提升药物浓度。
选用微波提取紫草及白芷中的有效成分。微波具有较好的穿透性和加热作用,被提取物从内部加热,微波辐射能富集药材有效成分,操作时间短、溶剂耗量少、有效成分得率高、不产生噪音,适用于热不稳定物质的提取。选用该方法提取能减少白芷挥发油的丢失,同时减少不耐热的紫草醌(150℃以下稳定)的损耗。
下面结合具体实施例对本发明进行进一步阐述。
本发明所述复方紫草膏的制备方法还包括原料预处理步骤,具体是将黄连、大黄、虎杖、地榆、生甘草、白芷和紫草经清洗、除杂后,控水25~40min,之后置于60~70℃的烘箱内烘干。上述处理好的原料作为后续实验使用。
实施例1
一种复方紫草膏,以重量份计,包括如下组分:紫草30份、黄连50份、大黄40份、虎杖40份、地榆30份、白芷25份、生甘草20份、山茶油450份、蜂蜡80份和冰片10份。
所述复方紫草膏的制备方法,包括如下步骤:
S1、以重量份计,将50份黄连、40份大黄、40份虎杖、30份地榆和20份生甘草分别粉碎、过80目筛网,之后混合,得到物料A;将30份紫草和25份白芷分别粉碎、过50目筛网,之后与450份山茶油混合,得到物料B;将10份冰片粉碎、过120目筛网,得到物料C;将80份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加质量浓度为60%的乙醇,所述乙醇的添加量为物料A体积的6倍,所述植物复合水解酶的终浓度为2.5U/ml,之后调节溶液的pH至5.0;接着置于超声破碎仪中恒温酶解,所述超声破碎仪的参数如下:温度45℃、频率35KHz、功率290W,超声破碎2h,然后过滤得到滤液,再向药渣中加入4倍体积的质量浓度为60%的乙醇回流提取2h,收集回流提取液并合并两次的药液,在-0.04Mpa,70℃的条件下减压回收乙醇,浓缩至相对密度为1.10的混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,其步骤如下:将浸膏分散溶解于水中,使浸膏水溶液浓度为0.5g/ml;以质量浓度为5%的乙醇洗脱1倍树脂体积进行大孔吸附树脂串联吸附柱(D-101和AB-8)预处理除杂,然后将所述浸膏水溶液通过所述大孔吸附树脂串联吸附柱,浸膏水溶液上样量与树脂量之比为1:10,吸附流速为3BV/h,吸附完成后,用质量浓度为70%的乙醇洗脱4倍树脂体积,洗脱流速为3BV/h,收集乙醇洗脱液,在-0.04Mpa,70℃的条件下下减压回收乙醇,经喷雾干燥,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述微波提取器的提取参数如下:700W的功率,提取15min;所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D在70℃的条件下混合均匀,过100目筛网后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
实施例2
一种复方紫草膏,以重量份计,包括如下组分:紫草40份、黄连60份、大黄50份、虎杖50份、地榆35份、白芷30份、生甘草25份、山茶油480份、蜂蜡90份和冰片12份。
所述复方紫草膏的制备方法,包括如下步骤:
S1、以重量份计,将60份黄连、50份大黄、50份虎杖、35份地榆和25份生甘草分别粉碎、过65目筛网,之后混合,得到物料A;将40份紫草和30份白芷分别粉碎、过40目筛网,之后与480份山茶油混合,得到物料B;将12份冰片粉碎、过110目筛网,得到物料C;将90份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加质量浓度为65%的乙醇,所述乙醇的添加量为物料A体积的7倍,所述植物复合水解酶的终浓度为2.8U/ml,之后调节溶液的pH至5.5;接着置于超声破碎仪中恒温酶解,所述超声破碎仪的参数如下:温度50℃、频率40KHz、功率300W,超声破碎2.5h,然后过滤得到滤液,再向药渣中加入5倍体积的质量浓度为65%的乙醇回流提取3h,收集回流提取液并合并两次的药液,在-0.04Mpa,70℃的条件下减压回收乙醇,浓缩至相对密度为1.12的混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,其步骤如下:将浸膏分散溶解于水中,使浸膏水溶液浓度为0.8g/ml;以质量浓度为5%的乙醇洗脱2倍树脂体积进行大孔吸附树脂串联吸附柱(D-101和AB-8)预处理除杂,然后将所述浸膏水溶液通过所述大孔吸附树脂串联吸附柱,浸膏水溶液上样量与树脂量之比为1:10,吸附流速为6BV/h,吸附完成后,用质量浓度为70%的乙醇洗脱5倍树脂体积,洗脱流速为6BV/h,收集乙醇洗脱液,在-0.04Mpa,70℃的条件下下减压回收乙醇,经喷雾干燥,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述微波提取器的提取参数如下:750W的功率,提取20min;所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D在75℃的条件下混合均匀,过90目筛网后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
实施例3
一种复方紫草膏,以重量份计,包括如下组分:紫草50份、黄连75份、大黄55份、虎杖55份、地榆45份、白芷35份、生甘草30份、山茶油500份、蜂蜡100份和冰片15份。
所述复方紫草膏的制备方法,包括如下步骤:
S1、以重量份计,将75份黄连、55份大黄、55份虎杖、45份地榆和30份生甘草分别粉碎、过50目筛网,之后混合,得到物料A;将50份紫草和35份白芷分别粉碎、过30目筛网,之后与500份山茶油混合,得到物料B;将15份冰片粉碎、过100目筛网,得到物料C;将100份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加质量浓度为70%的乙醇,所述乙醇的添加量为物料A体积的8倍,所述植物复合水解酶的终浓度为3U/ml,之后调节溶液的pH至6.0;接着置于超声破碎仪中恒温酶解,所述超声破碎仪的参数如下:温度60℃、频率45KHz、功率310W,超声破碎3h,然后过滤得到滤液,再向药渣中加入6倍体积的质量浓度为70%的乙醇回流提取4h,收集回流提取液并合并两次的药液,在-0.04Mpa,70℃的条件下减压回收乙醇,浓缩至相对密度为1.15的混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,其步骤如下:将浸膏分散溶解于水中,使浸膏水溶液浓度为1g/ml;以质量浓度为5%的乙醇洗脱3倍树脂体积进行大孔吸附树脂串联吸附柱(D-101和AB-8)预处理除杂,然后将所述浸膏水溶液通过所述大孔吸附树脂串联吸附柱,浸膏水溶液上样量与树脂量之比为1:10,吸附流速为9BV/h,吸附完成后,用质量浓度为70%的乙醇洗脱6倍树脂体积,洗脱流速为9BV/h,收集乙醇洗脱液,在-0.04Mpa,70℃的条件下下减压回收乙醇,经喷雾干燥,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述微波提取器的提取参数如下:800W的功率,提取30min;所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D在80℃的条件下混合均匀,过80目筛网后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
对比例1
同实施例2的制备方法基本一致,不同之处在于步骤S2中,不添加植物复合水解酶。
对比例2
同实施例2的制备方法基本一致,不同之处在于步骤S2中,物料A中加入植物复合水解酶后,直接酶解2.5h,不使用超声破碎仪进行超声酶解。
对比例3
同实施例2的制备方法基本一致,不同之处在于步骤S2中,不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤。
对比例4
同实施例2的制备方法基本一致,不同之处在于步骤S2中,不添加植物复合水解酶,同时不使用超声破碎仪进行超声破碎。
对比例5
同实施例2的制备方法基本一致,不同之处在于步骤S2中,不添加植物复合水解酶,同时不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤。
对比例6
同实施例2的制备方法基本一致,不同之处在于步骤S2中,不使用超声破碎仪进行超声破碎,同时不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤。
实施例4
婴幼儿湿疹治疗临床试验,与丁酸氢化可的松软膏(尤卓尔软膏)进行对比。
1)受试对象200例;
2)治疗方法:使用时,将适量药膏涂擦于湿疹区域,轻柔按摩促进吸收,每天用药2-3次;
3)治疗效果:参照中医病证诊断疗效标准,观察治疗前后瘙痒程度的轻重、湿疹面积大小、皮疹的形态和色泽(丘疹、皮损色泽、糜烂、油腻性鳞屑、结痂、渗液、抓痕)等临床表现,疗效分为四个标准:
治愈:患儿皮损完全消退,无干燥及瘙痒等自觉症状;
显效:患儿皮损消退>70%,干燥及瘙痒等症状明显减轻;
有效:患儿皮损消退>30%,仍有瘙痒及干燥感;
无效:患儿皮损消退<30%,瘙痒及干燥症状无减轻甚至加重。
总体有效率=治愈+显效+有效。
表1治疗效果表
从表1的结果可以看出,实施例1-3的平均治疗天数小于对比例1-6,对比例1-6与实施例1-3的区别在于,步骤S2中,缺少不添加植物复合水解酶、不使用超声破碎仪进行超声破碎和不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤的一种或者两种,导致对比例1-6中制得的复方紫草膏有效成分没有被完全提取,进而使得其治疗效果较差;实验结果表明,实施例1-3中,添加植物复合水解酶、使用超声破碎仪进行超声破碎酶解和进行大孔树脂吸附对所述混合浸膏进行精制操作步骤之间通过协同作用,最大程度地使原料中的有效成分被提取,各个有效组分之间通过协同作用,加快了治疗时间;同时,实施例2制得的复方紫草膏治疗效果要优于市售尤卓尔软膏。
实施例5
婴幼儿红臀治疗临床试验,与赛肤润进行对比。
1)受试对象200例;
2)治疗方法:患儿均给予相应的臀部护理,每次排便后用温水清洗臀部,更换尿布。观察组更换尿布时采用实施例所制备油膏局部外涂,每日3次,对照组使用赛肤润油外涂;
3)诊断分度根据尿布疹的分度标准:
轻度:皮肤潮红;
重I度:局部皮肤潮红,伴少许皮疹;
重Ⅱ度:局部皮肤潮红伴大量皮疹,并有部分皮肤呈点状或小片状破损;
重Ⅲ度:局部皮肤大片糜烂或表皮脱落,并伴有细菌或真菌感染。
4)疗效判断标准:
治愈:臀部皮肤红肿消退.皮疹、糜烂等症状消失,与肛周的皮肤无明显差异;
显效:患处皮肤症状明显减轻,范围缩小1/2以上;
有效:患处皮肤症状减轻,范围缩小1/3以上;
无效:无明显变化。
总体有效率=治愈+显效+有效。
表2治疗效果表
从表2的结果可以看出,实施例1-3的平均治疗天数小于对比例1-6,总有效率优于对比例1-6,对比例1-6与实施例1-3的区别在于,步骤S2中,缺少不添加植物复合水解酶、不使用超声破碎仪进行超声破碎和不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤的一种(对比例1-3)或者两种(对比例4-6),导致对比例1-6中制得的复方紫草膏有效成分没有被完全提取,进而使得其治疗效果较差,尤其是对比例4-6,其治愈人数远低于实施例1-3,这是由于对比例4-6制得的复方紫草膏中有效成分含量低,导致药效差;实验结果表明,实施例1-3中,添加植物复合水解酶、使用超声破碎仪进行超声破碎酶解和进行大孔树脂吸附对所述混合浸膏进行精制操作步骤之间通过协同作用,最大程度地使原料中的有效成分被提取,各个有效组分之间通过协同作用,加快了治疗时间;同时,实施例2制得的复方紫草膏治疗效果要优于市售赛肤润。
实施例6
烧烫伤临床试验,与市售京万红烫伤膏进行对比。
1)受试对象200例,均为不同部位的I度和II度烧烫伤;
2)治疗方法:使用时,对创口清理后外敷膏剂,覆盖无菌纱布,I度及浅II度烧烫伤每天用药1次,深II度烧烫伤每天用药2次,每次换药时用生理盐水清洗
3)诊断标准:
I度(红斑):轻度红肿热痛,感觉过敏,未起水泡,表皮干燥;
II度(水泡):浅II度:剧痛,感觉过敏,温度增高,有水疱,基底潮湿,呈均匀红色,水肿明显;深II度:痛觉迟钝,水疱有或无,揭去表皮,基底干燥苍白,有小出血点,水肿明显。
4)治疗效果:根据国家中医药管理局制定的《中医病证诊断疗效标准》判定:
治愈:全身症状消失,创面愈合:
好转:全身症状消失,创面未完全愈合:
未愈:全身症状未见改善,创面感染不能控制。
表3治疗效果表
例数 | 治愈 | 好转 | 未愈 | 平均治疗时间(天) | |
实施例1 | 20 | 17 | 3 | 0 | 4.2 |
实施例2 | 20 | 18 | 2 | 0 | 3.5 |
实施例3 | 20 | 16 | 4 | 0 | 3.7 |
对比例1 | 20 | 14 | 5 | 1 | 4.5 |
对比例2 | 20 | 14 | 4 | 2 | 5.2 |
对比例3 | 20 | 12 | 7 | 1 | 5.3 |
对比例4 | 20 | 11 | 7 | 2 | 5.5 |
对比例5 | 20 | 9 | 8 | 3 | 5.7 |
对比例6 | 20 | 7 | 8 | 5 | 6.2 |
京万红烫伤膏 | 20 | 15 | 5 | 0 | 4.2 |
从表3的结果可以看出,实施例1-3的平均治疗天数小于对比例1-6,实施例1-3试验对象没有未愈的,对比例1-6中的试验对象未愈的人数逐步增加,对比例1-6与实施例1-3的区别在于,步骤S2中,缺少不添加植物复合水解酶、不使用超声破碎仪进行超声破碎和不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤的一种或者两种,导致对比例1-6中制得的复方紫草膏有效成分没有被完全提取,进而使得其治疗效果较差;实验结果表明,实施例1-3中,添加植物复合水解酶、使用超声破碎仪进行超声破碎酶解和进行大孔树脂吸附对所述混合浸膏进行精制操作步骤之间通过协同作用,最大程度地使原料中的有效成分被提取,各个有效组分之间通过协同作用,加快了治疗时间;同时,实施例2制得的复方紫草膏治疗效果要优于市售京万红烫伤膏。
实施例7
静脉炎临床试验,与市售喜疗妥软膏进行对比。
1)受试对象200例,均为静脉输液所致静脉炎;
2)治疗方法:使用时,将适量药膏涂擦于肿胀变硬静脉表面,并轻柔按摩促进吸收,每天用药3-4次;
3)美国静脉输液护理学会(INS)静脉炎程度判断标准:
I度(红斑):轻度红肿热痛,感觉过敏,未起水泡,表皮干燥;
Ⅱ级:穿刺点疼痛,红、肿,静脉条索状改变,未触及硬结;
Ⅲ级:穿刺点疼痛,红、肿,静脉条索状改变,可触及硬结。
4)治疗效果:根据国家中医药管理局制定的《中医病证诊断疗效标准》判定,分治愈、显效、有效、无效四种:
治愈:疼痛消失,局部红肿消退,无触痛,血管变软,弹性恢复,血流通畅;
显效:疼痛减轻,局部无触痛,静脉变软,条索感减轻,血流通畅;
有效:触痛消失,瘀斑减轻,但仍有条索感,静脉变软不明显:
无效:经过治疗后仍有疼痛、红肿、静脉仍呈明显条索状者。
表4治疗效果表
例数 | 治愈 | 显效 | 有效 | 无效 | 总有效率 | |
实施例1 | 20 | 15 | 3 | 1 | 1 | 95% |
实施例2 | 20 | 17 | 1 | 1 | 1 | 95% |
实施例3 | 20 | 14 | 2 | 3 | 1 | 95% |
对比例1 | 20 | 12 | 3 | 2 | 3 | 85% |
对比例2 | 20 | 10 | 5 | 3 | 2 | 90% |
对比例3 | 20 | 9 | 6 | 2 | 3 | 85% |
对比例4 | 20 | 8 | 4 | 4 | 4 | 80% |
对比例5 | 20 | 7 | 6 | 2 | 5 | 75% |
对比例6 | 20 | 5 | 4 | 4 | 7 | 65% |
喜疗妥软膏 | 20 | 16 | 2 | 1 | 1 | 95% |
从表4的结果可以看出,实施例1-3的总有效率优于对比例1-6,对比例1-6与实施例1-3的区别在于,步骤S2中,缺少不添加植物复合水解酶、不使用超声破碎仪进行超声破碎和不进行大孔树脂吸附对所述混合浸膏进行精制操作步骤的一种(对比例1-3)或者两种(对比例4-6),导致对比例1-6中制得的复方紫草膏有效成分没有被完全提取,进而使得其治疗效果较差,尤其是对比例4-6,其治愈人数远低于实施例1-3,这是由于对比例4-6制得的复方紫草膏中有效成分含量低,导致药效差;实验结果表明,实施例1-3中,添加植物复合水解酶、使用超声破碎仪进行超声破碎酶解和进行大孔树脂吸附对所述混合浸膏进行精制操作步骤之间通过协同作用,最大程度地使原料中的有效成分被提取,各个有效组分之间通过协同作用,加快了治疗时间;同时,实施例2制得的复方紫草膏治疗效果要优于市售喜疗妥软膏。另外,本发明药膏组分科学配比协同作用,提高了药膏的治疗效果,实现快速镇痛,患处快速康复,避免患处的感染,减轻了治疗痛苦,缩短治疗时间,降低了患者及家属的经济负担。
实施例8典型案例
病例1患儿,男,1岁7月。出生后臀部、肛周反复红疹、红斑,伴瘙痒、渗出,予痱子粉、肤乐护理霜外用,效不佳,近1周大便次数增多,变稀,哭闹加重,遂来诊。
查体:臀部、肛周红斑、红疹,肛周渗出明显,伴有瘙痒,患儿纳少,烦躁,夜间哭闹明显,大便稀,每日6-7次,水样,夹有不消化奶瓣。
中医诊断:小儿泄泻(湿热型),治疗原则:清热利湿,升阳止泻。此外予复方紫草膏外搽肛周,2-3次/天。嘱家长减少患儿洗澡次数,禁用肥皂等,减少局部刺激,注意臀部皮肤清洁,干燥,勤换纸尿裤,乳母忌食辛辣、油腻、湿热等食物。3天后患儿复诊,大便恢复正常,2-3次/天,质稠,量可;肛周明显渗出减少,臀部红斑色减淡;继予复方紫草膏外用。一周后复诊,患儿肛周恢复正常,未见渗出,红斑消退;1个月后随访,未见复发。
病例2患儿,男,8个月。患儿“湿疹”6个月余,先后予炉甘石洗剂,布地奈德乳膏,透明质酸酶修复膜,肤乐护理霜外用,效欠佳,湿疹反复,皮疹时轻时重,遂来诊。
查体:双侧面颊部红斑伴丘疹,耳后渗出明显,躯干散在丘疹,肘部一处渗出样皮疹,伴有瘙痒,抓挠明显。家长述患儿服药困难,要求中药外用。予复方紫草油外用涂擦治疗,嘱家属每日清洁患处皮肤后,保持干燥,棉棒蘸取复方紫草油膏,外搽患处,2-3次/天,避免局部热水刺激,并嘱患儿及乳母均清淡饮食,忌牛、羊肉、海鲜,注意心情平稳。3天后微信复诊家长述患儿红斑较前变淡,渗出减少,继续复方紫草膏外用。2周后门诊复诊,患儿红斑基本消退,无渗出,皮肤残留少许干性结痂。1月后随访,未见再发。
病例3患者,女,76岁,因中风后遗症(8年),双下肢瘫痪常年卧床,骶尾部皮损。入院时诊为:Ⅲ-Ⅳ期压疮,重度营养不良。患者压疮史1年半,骶尾部处创面5cm×4.5cm×3.5cm,有黑色结痂,存在窦道,入院前曾先后使用康复新液,保赫曼银离子敷料、生肌玉红膏外用治疗,但效果欠佳,入院后给予清除压疮溃疡面坏死组织,然后用1%过氧化氢溶液和0.5%苯扎溴铵溶液清洗,再用生理盐水清洗创面,剪开窦道彻底清创,去除坏死组织及脓液,以无菌纱布吸干创面后,填塞复方紫草膏油纱布,再以纱布覆盖、固定,外层黏附减压贴。每日换药一次,经过2周治疗后患者压疮全部愈合,原创面仅残留少许疤痕。
病例4患儿,女,3岁。1天前被蚊虫叮咬左侧手背,被蚊虫叮咬后,出现瘙痒剧烈,患儿哭闹,局部明显肿胀伴有少许渗出症状,以复方紫草膏外涂每日3-4次,避免搔抓,次日患儿手背消肿,3天红斑皮损全部消退,未见明显感染表现。
病例5患者,男,54岁。因“胃癌”在我院治疗,给予静脉化疗2天后,出现输液局部多支静脉条索样改变,伴有疼痛不适,局部红肿。主治医生安排超声检查,提示浅静脉静脉壁增厚毛糙,血流缓慢,深静脉通畅,诊断考虑化疗后静脉炎。遂给予复方紫草膏外涂,每日3-4次,次日患者自觉疼痛减轻,局部肿胀好转,用药3日后随访,条索样静脉已软化,局部红肿消退,疼痛完全缓解。患者自述后续化疗时涂擦药膏区域未见再次发生静脉炎,复方紫草膏不仅能治疗已有静脉炎,还可能对未发生的静脉炎起到了预防的效果。
病例6患者,女,32岁。在“艾灸治疗”过程中出现脐部浅II度烧伤,查体见水疱形成,基底潮红,痛觉过敏。自行活力碘消毒后给予复方紫草膏外用,涂布2毫米厚油膏,敷贴覆盖。涂药后十分钟,患者疼痛明显减轻,翌日患者换药见创面红肿明显好转,少许渗出,基本无疼痛,未见感染。继续外敷药物两天,创面即完全愈合,少许结痂,结痂脱落后未遗留疤痕。
以上实施例,仅为本发明的具体实施方式,用以说明本发明的技术方案,而非对其限制,本发明的保护范围并不局限于此,尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,其依然可以对前述实施例所记载的技术方案进行修改或可轻易想到变化,或者对其中部分技术特征进行等同替换;而这些修改、变化或者替换,并不使相应技术方案的本质脱离本发明实施例技术方案的精神和范围,都应涵盖在本发明的保护范围之内。
Claims (10)
1.一种复方紫草膏,其特征在于,以重量份计,包括如下组分:紫草30~50份、黄连50~75份、大黄40~55份、虎杖40~55份、地榆30~45份、白芷25~35份、生甘草20~30份、山茶油450~500份、蜂蜡80~100份和冰片10~15份。
2.如权利要求1所述的复方紫草膏,其特征在于,以重量份计,包括如下组分:紫草40份、黄连60份、大黄50份、虎杖50份、地榆35份、白芷30份、生甘草25份、山茶油480份、蜂蜡90份和冰片12份。
3.一种复方紫草膏的制备方法,其特征在于,包括如下步骤:
S1、以重量份计,将50~75份黄连、40~55份大黄、40~55份虎杖、30~45份地榆和20~30份生甘草分别粉碎、过筛网,之后混合,得到物料A;将30~50份紫草和25~35份白芷分别粉碎、过筛网,之后与450~500份山茶油混合,得到物料B;将10~15份冰片粉碎、过筛网,得到物料C;将80~100份蜂蜡加热融化,得到物料D;
S2、向步骤S1中所述的物料A中添加乙醇,植物复合水解酶,之后置于超声破碎仪中恒温酶解后,过滤、减压回收,得到混合浸膏;最后利用大孔树脂吸附法对所述混合浸膏进行精制,经喷雾干燥后,制得中药粉剂;
S3、将步骤S1中所述的物料B置于微波提取器中进行提取,得到提取液,所述提取液经抽滤后、取上清,得到浸提物;
S4、将步骤S2中制得的中药粉剂、步骤S3中得到的浸提物和步骤S1中的物料D混合均匀,过筛后,加入步骤S1中的物料C,再次混匀后,得到复方紫草膏。
4.如权利要求3所述的复方紫草膏的制备方法,其特征在于,所述制备方法还包括原料预处理步骤,具体是将黄连、大黄、虎杖、地榆、生甘草、白芷和紫草经清洗、除杂后,控水25~40min,之后置于60~70℃的烘箱内烘干。
5.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S1中,所述物料A中的原料过50~80目筛网;所述物料B中的紫草和白芷过30~50目筛网;所述物料C中的原料过100~120目筛网。
6.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S2中,所述乙醇的质量浓度为60~70%,所述乙醇的添加量为物料A体积的6~8倍,所述植物复合水解酶的终浓度为2.5~3U/ml,之后调节溶液的pH至5.0~6.0之间。
7.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S2中,所述超声破碎仪的参数如下:温度45~60℃、频率40±5KHz、功率300±10W,超声破碎2~3h,之后过滤得到滤液,再向药渣中加入4~6倍体积的质量浓度为60~70%的乙醇回流提取2~4h,收集回流提取液并合并两次的药液,在-0.04Mpa,70℃的条件下减压回收乙醇,浓缩至相对密度为1.10~1.15的混合浸膏。
8.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S2中,所述大孔树脂吸附法对所述混合浸膏进行精制的步骤如下:将浸膏分散溶解于水中,使浸膏水溶液浓度为0.5~1g/ml;以质量浓度为5%的乙醇洗脱1~3倍树脂体积进行大孔吸附树脂串联吸附柱(D-101和AB-8)预处理除杂,然后将所述浸膏水溶液通过所述大孔吸附树脂串联吸附柱,浸膏水溶液上样量与树脂量之比为1:10,吸附流速为3~9BV/h,吸附完成后,用质量浓度为70%的乙醇洗脱4~6倍树脂体积,洗脱流速为3~9BV/h,收集乙醇洗脱液,在-0.04Mpa,70℃的条件下下减压回收乙醇,经喷雾干燥,制得中药粉剂。
9.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S3中,所述微波提取器的提取参数如下:700~800W的功率,提取15~30min。
10.如权利要求3所述的复方紫草膏的制备方法,其特征在于,步骤S4中,所述混合均匀的温度为70~80℃,筛网的规格为80~100目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110775213.1A CN113332365B (zh) | 2021-07-08 | 2021-07-08 | 一种复方紫草膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110775213.1A CN113332365B (zh) | 2021-07-08 | 2021-07-08 | 一种复方紫草膏及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113332365A true CN113332365A (zh) | 2021-09-03 |
CN113332365B CN113332365B (zh) | 2022-09-27 |
Family
ID=77479352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110775213.1A Active CN113332365B (zh) | 2021-07-08 | 2021-07-08 | 一种复方紫草膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113332365B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048894A (zh) * | 2010-12-22 | 2011-05-11 | 陈远征 | 一种治疗烧伤的中药组合物及其制备方法 |
CN103655818A (zh) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | 一种治疗烫伤的药膏 |
CN103705613A (zh) * | 2012-10-09 | 2014-04-09 | 仇美秋 | 一种治疗烧烫伤的外用药 |
CN104491693A (zh) * | 2014-12-03 | 2015-04-08 | 王晋军 | 一种治疗溃疡阳证的中药消炎药膏 |
-
2021
- 2021-07-08 CN CN202110775213.1A patent/CN113332365B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048894A (zh) * | 2010-12-22 | 2011-05-11 | 陈远征 | 一种治疗烧伤的中药组合物及其制备方法 |
CN103705613A (zh) * | 2012-10-09 | 2014-04-09 | 仇美秋 | 一种治疗烧烫伤的外用药 |
CN103655818A (zh) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | 一种治疗烫伤的药膏 |
CN104491693A (zh) * | 2014-12-03 | 2015-04-08 | 王晋军 | 一种治疗溃疡阳证的中药消炎药膏 |
Non-Patent Citations (4)
Title |
---|
兰祖全: "冷水浴合虎黄烫伤油纱治疗烧烫伤85例", 《四川中医》 * |
李景珍: "复方紫草油的制备与临床应用", 《齐鲁药事》 * |
甘海芳等: "复方紫草油Ⅰ号与Ⅱ号治疗婴儿湿疹临床观察", 《中医药临床杂志》 * |
蔡国良: "烫伤药膏外用治疗烧伤360例", 《陕西中医》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113332365B (zh) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102302661A (zh) | 一种治疗皮肤病的中药组合物 | |
CN102861287B (zh) | 一种治疗湿热下注淤血型糖尿病足的中药组合物及其制备方法 | |
CN103520655B (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN101143171B (zh) | 一种中药药物、其制备方法及其应用 | |
CN106581439A (zh) | 一种治疗创伤、糖尿病足和皮肤溃烂的中药组合物及其制备方法 | |
CN106421392A (zh) | 一种治疗褥疮的中药凝胶剂及其制备方法 | |
CN105456498A (zh) | 治疗糖尿病足溃疡的中药制剂 | |
CN105853947A (zh) | 一种治疗肝硬化的中药制剂及其制备方法 | |
CN113332365B (zh) | 一种复方紫草膏及其制备方法 | |
CN108114090B (zh) | 一种治疗痔疮和烧烫伤的中药组合物 | |
CN105327244A (zh) | 一种含有艾叶的治疗褥疮的中药组合物及其制备方法 | |
CN107812091B (zh) | 一种治疗化疗药物引起的静脉炎的中药制剂及其制备方法 | |
CN100560100C (zh) | 蜈蚣褥疮液及其制备方法 | |
CN105031596A (zh) | 一种治疗钱币状湿疹的软膏及其制备方法 | |
CN104306734B (zh) | 治疗糖尿病坏疽外用膏药制剂及其制备方法 | |
CN111544523A (zh) | 一种治疗皮肤溃烂的中药组合物及其应用 | |
CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
CN104491327B (zh) | 一种用于治疗褥疮的喷雾药剂 | |
CN110664936A (zh) | 一种褥疮膏 | |
CN108567868A (zh) | 一种护肤溃愈外用中药组合物及其制备方法 | |
CN105168503B (zh) | 一种用于防治放射性皮炎的外用中药组合物及其制备方法 | |
CN108186807A (zh) | 一种治疗肛周疾病的中药组合物 | |
CN109303821A (zh) | 一种治疗烧烫伤、褥疮的外用药膏及制备使用方法 | |
CN108066466A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法与应用 | |
CN105125781A (zh) | 一种治疗iii期压疮的中药凝胶剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |